$MDT

Generating a unique summary for MDT…

AI-generated for information only — not investment advice.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Institutions hold 88.62% · insiders 0.34% · 2,939 institutions

Consensus score 1.77 (1 = strong buy, 5 = sell) · mean target 104.62

• BTIGBuymain2026-10-12
• BarclaysEqual-Weightinit2026-10-07
• TD CowenBuyreit2026-09-30
• UBSBuymain2026-09-03
• Truist SecuritiesHoldreit2026-09-02
• Wells FargoOverweightmain2026-09-02
• RBC CapitalOutperformreit2026-09-02
• B of A SecuritiesBuymain2026-09-02
• StifelHoldmain2026-09-02
• BairdNeutralmain2026-09-02

Next report: 2026-11-17

• 11-KAnnual report of employee stock purchase2026-10-21Open
• 8-KCorporate Changes & Voting Matters2026-10-19Open
• SC TO-I/ATender Offer/Acquisition Reports2026-10-14Open
• SC TO-I/ATender Offer/Acquisition Reports2026-10-13Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-09Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-08Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-07Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-06Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-05Open
• 425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions2026-10-02Open

• Medtronic (MDT) Reports Strong Real World Ablation Data At APHRS 2026

  Medtronic (NYSE:MDT) reported positive real world registry results for its Sphere-9 catheter and PulseSelect PFA System at APHRS 2026. The Sphere-9 catheter data covered both atrial and ventricular arrhythmias, with registry outcomes indicating high procedural success rates. PulseSelect PFA System findings highlighted a strong safety profile in everyday clinical use, beyond controlled trial settings. The Sphere-9 and PulseSelect registry findings matter, but investors should weigh more than...

  Sat, 24 Oct 2026 04:23:31 +0000

• Medtronic (MDT) Stock Could Be A Bargain On Cash Flow

  Medtronic has delivered a solid 51.6% share price gain over the past three years, while rolling out new cardiac devices and digital tools that could reshape how it earns and collects cash. With the stock around US$95.41, the open question is whether that price tag lines up with what the company’s cash flows can reasonably support. The 51.6% return over three years puts real weight on the issue of whether Medtronic’s current valuation can still be explained by its underlying cash...

  Sat, 24 Oct 2026 03:12:20 +0000

• Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players

  108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on GrowthDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive analysis of the global pacemakers market, covering revenue performance, growth prospects, technology developments, regulatory condition

  Fri, 23 Oct 2026 14:02:00 +0000

• Global Access Device Market Size, Share, Trends, and Forecast, 2026-2032: Trocar and Single-Port Access Devices | Market to Exceed $1.2 Billion as Advanced Trocars Drive Growth

  New Report available from Research and Markets, values access devices at just over $990m in 2025, led by Applied Medical, Ethicon and Medtronic — though reprocessing contracts and cheap Asia-Pacific disposables keep prices under pressureDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Access Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Trocar and Single-Port Access Devices" has been added to ResearchAndMarkets.com's offering. Global Access Device Market to Exceed $1.2 B

  Fri, 23 Oct 2026 13:26:00 +0000

• Medtronic reports real-world findings for cardiac ablation systems

  In the REAL PULSE prospective study, clinicians evaluated 1,160 AFib patients across 38 centres using the PulseSelect PFA system.

  Fri, 23 Oct 2026 09:53:40 +0000

• Global Intrathecal Pump Market Size, Share, Trends, and Forecast, 2026-2032 | Aging Demand and Longer-Life Devices Support a $360 Million Market by 2032

  New Report available from Research and Markets, finds Medtronic ahead of Flowonix and Tricumed in a $350m market expected to reach only about $360m by 2032, as high refill costs, ASP erosion and past recalls weighDublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Intrathecal Pump Market Size, Share & Trends Analysis | Global | 2026-2032" has been added to ResearchAndMarkets.com's offering. The global intrathecal pump market was valued at $350 million in 2025 and is projected to reach approximately $360

  Thu, 22 Oct 2026 13:31:00 +0000

• Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026

  Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).

  Thu, 22 Oct 2026 11:00:00 +0000

• Global Medical Devices Market Size, Share, and Growth Forecast to 2031 | Aging Populations Push the Global Medical Devices Market Toward $818 Billion

  The global medical devices market is projected to grow from $580.79 billion in 2026 to $817.78 billion by 2031, a new report finds, as chronic disease and hospital investment rise, though lengthy approvals and staff shortages weigh; Medtronic, Johnson & Johnson, Abbott and Siemens Healthineers are among 25 companies profiled.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Medical Devices Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global medical devices m

  Wed, 21 Oct 2026 09:03:00 +0000